HYTERA
21.4.2022 14:20:12 CEST | Business Wire | Press release
Hytera (SZSE: 002583), the leading global provider of professional communications technologies and solutions, has released its annual Corporate Responsibility Report recently, summarizing the company’s environmental, social and governance (ESG) performance in 2021.
As a leading player in the Professional Mobile Radio (PMR) industry, Hytera has a long history of providing stakeholders with transparent information on its annual sales and ESG performance. The report features successes achieved last year, including its performance on business development as well as environmental sustainability, as well as technical support for public events and disaster relief around the world.
Continuous Innovation to Lead the Industry Transformation
Hytera is focused on technological innovation to drive business development. By the end of 2021, Hytera's total R&D investment had increased to USD 162 million, accounting for 18.05% of the sales revenue, and R&D personnel accounted for over 40% of the staff. Hytera has filed for 2,892 patents in total, including 507 PCT patents, 291 overseas patents, and 79 5G and LEO satellites patents; the overall patent licensing rate has reached 93.32%.
Hytera’s PMR-LTE convergent solutions have been recognized by the market in the past few years and so far, Hytera has deployed more than 200 converged multi-media PTT platforms globally and has been cooperating with over 20 local operators to better serve more vertical industry uses. In 2021, the International Critical Communications Awards (ICAA) awarded Hytera the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC customer case using PMR-LTE convergent solutions.
Better Operation for Environmental Sustainability
Hytera is dedicated to operating with sustainable business practices, including energy saving, emission reduction, and green and recyclable product manufacturing management. In 2021, Hytera’s electricity consumption decreased by 25% YOY, and general industrial waste dropped by 22% YOY.
In 2021, Hytera's subsidiaries HMF and Teltronic have organized multiple Green Travel campaigns, which reduced 809 kg of carbon dioxide emissions, exhaust gas and noise pollution by bike cycling instead of car driving in commutes to work.
Participation in Social Activities and Community Service to Repay the Society
Hytera has actively contributed its capabilities to improve disease prevention, for example, donating two-way radios to staff in hospitals, medical teams and security departments around the world in order to combat COVID-19.
Hytera also actively participated in various social welfare activities. In late 2021, Hytera supported Tinzert Elementary School of Morocco with a donation of warm coats and medical masks, and renovated the school to withstand the coldness of the mountainous area. Besides, Hytera was recognized as the science and technology education center and set up technology tutorials for both students and adults utilizing the PMR technologies and devices.
In terms of disaster relief, Hytera provided professional communication supports to the local rescue teams for flood relief in Henan China, and western Germany. Hytera also provided support to Blue Sky Rescue (BSR) volunteers in Europe to empower their post-disaster rescue work.
This year, the world faced greater global challenges than ever before, necessitating the use of professional technologies and products. Hytera’s innovations in communications technologies are revolutionizing industries and addressing some of the society's serious challenges.
Hytera is proud of its efforts to protect the environment and keep the community safe, and everything it does is guided by the code of ethics and business conduct.
Hytera will continue to make contributions to the people, communities, and the environment in order to make the world more intelligently connected and to help shape a better future for everybody.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005570/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom